Infection in cystic fibrosis: Impact of the environment and climate

Expert Review of Respiratory Medicine

Volumn 10, Issue 5, 2016, Pages 505-519

  Ramsay, K A ^a,b   Stockwell, R E ^a   Bell, S C ^a,b,c   Kidd, T J ^b,d  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c THE PRINCE CHARLES HOSPITAL   (Australia)

^d QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

acquisition; climate; Cystic fibrosis; environmental microbiology; epidemiology; fungi; infection; nontuberculous mycobacteria; Pseudomonas aeruginosa; travel

Indexed keywords

ACHROMOBACTER; BURKHOLDERIA CEPACIA; CLIMATE; CYSTIC FIBROSIS; DISEASE EXACERBATION; ENVIRONMENTAL FACTOR; ENVIRONMENTAL TEMPERATURE; HAEMOPHILUS INFLUENZAE; HUMAN; PREVALENCE; PSEUDOMONAS AERUGINOSA; REVIEW; STAPHYLOCOCCUS AUREUS; STENOTROPHOMONAS MALTOPHILIA; SUMMER; ATYPICAL MYCOBACTERIOSIS; COMPLICATION; ENVIRONMENT; MICROBIOLOGY; MORTALITY; PROGNOSIS;

CLIMATE; CYSTIC FIBROSIS; ENVIRONMENT; HUMANS; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; PROGNOSIS; PSEUDOMONAS AERUGINOSA;

EID: 84961588671     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2016.1162715     Document Type: Review

References (142)

1. OSullivan BP, Freedman SD. Cystic fibrosis. Lancet. 2009; 373 (9678): 1891-1904.
2. Bell SC, De Boeck K, Amaral MD. New pharmacological approaches for cystic fibrosis: promises, progress, pitfalls. Pharmacol Ther. 2015; 145: 19-34.
3. Zolin AM, McKone EF, van Rens J. et al. European Cystic Fibrosis Patient Registry Annual Data Report 2010. 2014. [cited 2015 Aug 28]. Available from: www.ecfs.eu/projects/ecfs-patient-registry/annual-reports
4. UK CF Registry annual data report 2013. London (UK): © Cystic Fibrosis Trust; 2014. [cited 2015 Aug 28]. Available from: www.cysticfibrosis.org.uk/research-care/uk-cf-registry/cf-registry-reports
5. The Canadian cystic fibrosis registry 2012 annual report. Toronto (Ontario): Cystic Fibrosis Canada; 2014. [cited 2015 Aug 28]. Available from: www.cysticfibrosis.ca/news-and-media/publications/
6. Cystic fibrosis Australia 2013 16th annual report from the cystic fibrosis data registry. Sydney (Australia): Cystic Fibrosis Australia; 2015. [cited 2015 Aug 28]. Available from: www.cysticfibrosis.org.au/data-registry
7. Burgel PR, Bellis G, Olesen HV, et al. Future trends in cystic fibrosis demography in 34 European countries. Eur Respir J. 2015; 46 (1): 133-141.
8. Cystic Fibrosis Foundation Patient Registry 2014 Annual Data Report to the Center Directors. Bethesda, Maryland: © Cystic Fibrosis Foundation. 2015. [cited 2015 Aug 28]. Available from: www.cff.org/Our-Research/CF-Patient-Registry/
9. Burns JL, Gibson RL, McNamara S, et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis. 2001; 183 (3): 444-452.
10. MacKenzie T, Gifford AH, Sabadosa KA, et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the cystic fibrosis foundation patient registry. Ann Intern Med. 2014; 161 (4): 233-241.
11. Flume PA, Strange C, Ye X, et al. Pneumothorax in cystic fibrosis. Chest. 2005; 128 (2): 720-728.
12. Flume PA, Yankaskas JR, Ebeling M, et al. Massive hemoptysis in cystic fibrosis. Chest. 2005; 128 (2): 729-738.
13. Plant BJ, Goss CH, Plant WD, et al. Management of comorbidities in older patients with cystic fibrosis. Lancet Respir Med. 2013; 1 (2): 164-174.
14. Rabin HR, Butler SM, Wohl ME, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol. 2004; 37 (5): 400-406.
15. Bell SC, Reid DW. Challenges of the care of adults with cystic fibrosis. ERJ Monograph. 2014; 64: 287-304.
16. Parkins MD, Floto RA. Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis. J Cyst Fibros. 2015; 14 (3): 293-304.
17. Hirche TO, Bradley J, dAlquen D, et al. Travelling with cystic fibrosis: recommendations for patients and care team members. J Cyst Fibros. 2010; 9 (6): 385-399.
18. Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev. 2010; 23 (2): 299-323.
19. Bar-On O, Mussaffi H, Mei-Zahav M, et al. Increasing nontuberculous mycobacteria infection in cystic fibrosis. J Cyst Fibros. 2015; 14 (1): 53-62.
20. Qvist T, Gilljam M, Jonsson B, et al. Epidemiology of nontuberculous mycobacteria among patients with cystic fibrosis in Scandinavia. J Cyst Fibros. 2015; 14 (1): 46-52.
21. Kidd TJ, Whiley DM, Bell SC, et al. Pseudomonas. In: Liu D., editor. Molecular detection of human bacterial pathogens. Boca Raton (FL): CRC Press, Taylor and Francis Group; 2001. p. 1009-1022.
22. Anaissie EJ, Penzak SR, Dignani MC. The hospital water supply as a source of nosocomial infections: a plea for action. Arch Intern Med. 2002; 162 (13): 1483-1492.
23. Kidd TJ, Ritchie SR, Ramsay KA, et al. Pseudomonas aeruginosa exhibits frequent recombination, but only a limited association between genotype and ecological setting. PLoS One. 2012; 7 (9): e44199.
24. Ogbulie JN, Adieze IE, Nwankwo NC. Susceptibility pattern of some clinical bacterial isolates to selected antibiotics and disinfectants. Pol J Microbiol. 2008; 57 (3): 199-204.
25. Pirnay JP, Matthijs S, Colak H, et al. Global Pseudomonas aeruginosa biodiversity as reflected in a Belgian river. Environ Microbiol. 2005; 7 (7): 969-980.
26. Remold SK, Brown CK, Farris JE, et al. Differential habitat use and niche partitioning by Pseudomonas species in human homes. Microb Ecol. 2011; 62 (3): 505-517.
27. Pirnay JP, Bilocq F, Pot B, et al. Pseudomonas aeruginosa population structure revisited. PLoS One. 2009; 4 (11): e7740.
28. Roland PS, Stroman DW. Microbiology of acute otitis externa. Laryngoscope. 2002; 112 (7 Pt 1): 1166-1177.
29. Green M, Apel A, Stapleton F. Risk factors and causative organisms in microbial keratitis. Cornea. 2008; 27 (1): 22-27.
30. Stapleton F, Keay LJ, Sanfilippo PG, et al. Relationship between climate, disease severity, and causative organism for contact lens-associated microbial keratitis in Australia. Am J Ophthalmol. 2007; 144 (5): 690-698.
31. Perencevich EN, McGregor JC, Shardell M, et al. Summer peaks in the incidences of gram-negative bacterial infection among hospitalized patients. Infect Control Hosp Epidemiol. 2008; 29 (12): 1124-1131.
32. Tucker P, Gilliland J. The effect of season and weather on physical activity: a systematic review. Public Health. 2007; 121 (12): 909-922.
33. Cappello S, Guglielmino SPP. Effects of growth temperature on polystyrene adhesion of Pseudomonas aeruginosa ATCC 27853. Braz J Microbiol. 2006; 37 (3): 205-207.
34. Hostacka A, Ciznar I, Stefkovicova M. Temperature and pH affect the production of bacterial biofilm. Folia Microbiol (Praha). 2010; 55 (1): 75-78.
35. Abdallah M, Benoliel C, Ferreira-Theret P, et al. Effect of culture conditions on the resistance of Pseudomonas aeruginosa biofilms to disinfecting agents. Biofouling. 2015; 31 (1): 49-59.
36. Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs. 2007; 67 (3): 351-368.
37. Llanes C, Pourcel C, Richardot C, et al. Diversity of beta-lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study. J Antimicrob Chemother. 2013; 68 (8): 1763-1771.
38. Hogardt M, Heesemann J. Microevolution of Pseudomonas aeruginosa to a chronic pathogen of the cystic fibrosis lung. Curr Top Microbiol Immunol. 2013; 358: 91-118.
39. Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002; 34 (2): 91-100.
40. Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med. 2003; 168 (8): 918-951.
41. Cystic Fibrosis Foundation Patient Registry 2013 Annual Data Report to the Center Directors. Bethesda, Maryland: © Cystic Fibrosis Foundation. 2014. [cited 2015 Aug 28]. Available from: www.cff.org/Our-Research/CF-Patient-Registry/
42. Hansen CR, Pressler T, Hoiby N. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. J Cyst Fibros. 2008; 7 (6): 523-530.
43. Kidd TJ, Ramsay KA, Vidmar S, et al. Pseudomonas aeruginosa genotypes acquired by children with cystic fibrosis by age 5-years. J Cyst Fibros. 2015; 14 (3): 361-369.
44. Ranganathan SC, Skoric B, Ramsay KA, et al. Geographical differences in first acquisition of Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc. 2013; 10 (2): 108-114.
45. Kidd TJ, Ramsay KA, Hu H, et al. Shared Pseudomonas aeruginosa genotypes are common in Australian cystic fibrosis centres. Eur Respir J. 2013; 41 (5): 1091-1100.
46. Fothergill JL, Walshaw MJ, Winstanley C. Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections. Eur Respir J. 2012; 40 (1): 227-238.
47. Jones AM, Govan JR, Doherty CJ, et al. Identification of airborne dissemination of epidemic multiresistant strains of Pseudomonas aeruginosa at a CF centre during a cross infection outbreak. Thorax. 2003; 58 (6): 525-527.
48. Knibbs LD, Johnson GR, Kidd TJ, et al. Viability of Pseudomonas aeruginosa in cough aerosols generated by persons with cystic fibrosis. Thorax. 2014; 69 (8): 740-745.
49. Johansen HK, Hoiby N. Seasonal onset of initial colonisation and chronic infection with Pseudomonas aeruginosa in patients with cystic fibrosis in Denmark. Thorax. 1992; 47 (2): 109-111.
50. Psoter KJ, De Roos AJ, Wakefield J, et al. Season is associated with Pseudomonas aeruginosa acquisition in young children with cystic fibrosis. Clin Microbiol Infect. 2013; 19 (11): E483-E489.
51. Collaco JM, McGready J, Green DM, et al. Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study. PLoS One. 2011; 6 (11): e27784.
52. Psoter KJ, Der AJ, Wakefield J, et al. Association of meteorological and geographical factors and risk of initial Pseudomonas aeruginosa acquisition in young children with cystic fibrosis. Epidemiol Infect. 2016; 144 (5): 1075-1083.
53. Kopp BT, Nicholson L, Paul G, et al. Geographic variations in cystic fibrosis: an analysis of the U.S. CF Foundation Registry. Pediatr Pulmonol. 2015; 50 (8): 754-762.
54. Psoter KJ, Rosenfeld M, De Roos AJ, et al. Differential geographical risk of initial Pseudomonas aeruginosa acquisition in young US children with cystic fibrosis. Am J Epidemiol. 2014; 179 (12): 1503-1513.
55. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001; 32 (4): 277-287.
56. Purdy-Gibson ME, France M, Hundley TC, et al. Pseudomonas aeruginosa in CF and non-CF homes is found predominantly in drains. J Cyst Fibros. 2015; 14 (3): 341-346.
57. Rosenfeld M, Emerson J, McNamara S, et al. Risk factors for age at initial Pseudomonas acquisition in the cystic fibrosis epic observational cohort. J Cyst Fibros. 2012; 11 (5): 446-453.
58. Goeminne PC, Nawrot TS, De Boeck K, et al. Proximity to blue spaces and risk of infection with Pseudomonas aeruginosa in cystic fibrosis: a case-control analysis. J Cyst Fibros. 2015; 14 (6): 741-747.
59. Coenye T, Vandamme P. Diversity and significance of Burkholderia species occupying diverse ecological niches. Environ Microbiol. 2003; 5 (9): 719-729.
60. Compant S, Nowak J, Coenye T, et al. Diversity and occurrence of Burkholderia spp. in the natural environment. FEMS Microbiol Rev. 2008; 32 (4): 607-626.
61. Coenye T, Laevens S, Willems A, et al. Burkholderia fungorum sp. nov. and Burkholderia caledonica sp. nov., two new species isolated from the environment, animals and human clinical samples. Int J Syst Evol Microbiol. 2001; 51 (Pt 3): 1099-1107.
62. OCarroll MR, Kidd TJ, Coulter C, et al. Burkholderia pseudomallei: another emerging pathogen in cystic fibrosis. Thorax. 2004; 58 (12): 1087-1091.
63. Zlosnik JE, Zhou G, Brant R, et al. Burkholderia species infections in patients with cystic fibrosis in British Columbia, Canada. 30 years experience. Ann Am Thorac Soc. 2015; 12 (1): 70-78.
64. Geake JB, Reid DW, Currie BJ, et al. An international, multicentre evaluation and description of Burkholderia pseudomallei infection in cystic fibrosis. BMC Pulm Med. 2015; 15: 116.
65. Smet B, Mayo M, Peeters C, et al. Burkholderia stagnalis sp. nov. and Burkholderia territorii sp. nov., two novel Burkholderia cepacia complex species from environmental and human sources. Int J Syst Evol Microbiol. 2015; 65: 2265-2271.
66. Ramsay KA, Butler CA, Paynter S, et al. Factors influencing acquisition of Burkholderia cepacia complex organisms in patients with cystic fibrosis. J Clin Microbiol. 2013; 51 (12): 3975-3980.
67. LiPuma JJ. Burkholderia and emerging pathogens in cystic fibrosis. Semin Respir Crit Care Med. 2003; 24 (6): 681-692.
68. Kidd TJ, Douglas JM, Bergh HA, et al. Burkholderia cepacia complex epidemiology in persons with cystic fibrosis from Australia and New Zealand. Res Microbiol. 2008; 159 (3): 194-199.
69. Currie BJ. Melioidosis: evolving concepts in epidemiology, pathogenesis, and treatment. Semin Respir Crit Care Med. 2015; 36 (1): 111-125.
70. Inglis TJ, Sagripanti JL. Environmental factors that affect the survival and persistence of Burkholderia pseudomallei. Appl Environ Microbiol. 2006; 72 (11): 6865-6875.
71. Wiersinga WJ, Currie BJ, Peacock SJ. Melioidosis. N Engl J Med. 2012; 367 (11): 1035-1044.
72. Sun H, Shi B, Bai Y, et al. Bacterial community of biofilms developed under different water supply conditions in a distribution system. Sci Total Environ. 2014; 472: 99-107.
73. Amoureux L, Bador J, Fardeheb S, et al. Detection of Achromobacter xylosoxidans in hospital, domestic, and outdoor environmental samples and comparison with human clinical isolates. Appl Environ Microbiol. 2013; 79 (23): 7142-7149.
74. Ridderberg W, Bendstrup KE, Olesen HV, et al. Marked increase in incidence of Achromobacter xylosoxidans infections caused by sporadic acquisition from the environment. J Cyst Fibros. 2011; 10 (6): 466-469.
75. Wittmann J, Dreiseikelmann B, Rohde C, et al. Isolation and characterization of numerous novel phages targeting diverse strains of the ubiquitous and opportunistic pathogen Achromobacter xylosoxidans. PLoS One. 2014; 9 (1): e86935.
76. Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012; 25 (1): 2-41.
77. van der Wielen PW, Van Der Kooij D. Nontuberculous mycobacteria, fungi, and opportunistic pathogens in unchlorinated drinking water in The Netherlands. Appl Environ Microbiol. 2013; 79 (3): 825-834.
78. De Baets F, Schelstraete P, Van Daele S, et al. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. J Cyst Fibros. 2007; 6 (1): 75-78.
79. Hansen CR, Pressler T, Nielsen KG, et al. Inflammation in Achromobacter xylosoxidans infected cystic fibrosis patients. J Cyst Fibros. 2010; 9 (1): 51-58.
80. Lambiase A, Catania MR, Del Pezzo M, et al. Achromobacter xylosoxidans respiratory tract infection in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis. 2011; 30 (8): 973-980.
81. Goss CH, Mayer-Hamblett N, Aitken ML, et al. Association between Stenotrophomonas maltophilia and lung function in cystic fibrosis. Thorax. 2004; 59 (11): 955-959.
82. Waters V, Atenafu EG, Lu A, et al. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros. 2013; 12 (5): 482-486.
83. Waters V, Yau Y, Prasad S, et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med. 2011; 183 (5): 635-640.
84. Festini F, Taccetti G, Mannini C, et al. Patient risk of contact with respiratory pathogens from inanimate surfaces in a cystic fibrosis outpatient clinic. A prospective study over a four-year period. Pediatr Pulmonol. 2007; 42 (9): 779-784.
85. Hansen CR, Pressler T, Ridderberg W, et al. Achromobacter species in cystic fibrosis: cross-infection caused by indirect patient-to-patient contact. J Cyst Fibros. 2013; 12 (6): 609-615.
86. Kanellopoulou M, Pournaras S, Iglezos H, et al. Persistent colonization of nine cystic fibrosis patients with an Achromobacter (Alcaligenes) xylosoxidans clone. Eur J Clin Microbiol Infect Dis. 2004; 23 (4): 336-339.
87. Van Daele S, Verhelst R, Claeys G, et al. Shared genotypes of Achromobacter xylosoxidans strains isolated from patients at a cystic fibrosis rehabilitation center. J Clin Microbiol. 2005; 43 (6): 2998-3002.
88. Brooke JS, Annand JW, Hammer A, et al. Investigation of bacterial pathogens on 70 frequently used environmental surfaces in a large urban U.S. university. J Environ Health. 2009; 71 (6): 17-22.
89. Schable B, Villarino ME, Favero MS, et al. Application of Multilocus enzyme electrophoresis to epidemiologic investigations of Xanthomonas maltophilia. Infect Control Hosp Epidemiol. 1991; 12 (3): 163-167.
90. Nicoletti M, Iacobino A, Prosseda G, et al. Stenotrophomonas maltophilia strains from cystic fibrosis patients: genomic variability and molecular characterization of some virulence determinants. Int J Med Microbiol. 2011; 301 (1): 34-43.
91. Pompilio A, Pomponio S, Crocetta V, et al. Phenotypic and genotypic characterization of Stenotrophomonas maltophilia isolates from patients with cystic fibrosis: genome diversity, biofilm formation, and virulence. BMC Microbiol. 2011; 11: 159.
92. King P. Haemophilus influenzae and the lung (Haemophilus and the lung). Clin Transl Med. 2012; 1 (1): 10.
93. Rubach MP, Bender JM, Mottice S, et al. Increasing incidence of invasive Haemophilus influenzae disease in adults, Utah, USA. Emerg Infect Dis. 2011; 17 (9): 1645-1650.
94. Sollid JU, Furberg AS, Hanssen AM, et al. Staphylococcus aureus: determinants of human carriage. Infect Genet Evol. 2014; 21: 531-541.
95. Korzeniewski K, Nitsch-Osuch A, Lass A, et al. Respiratory infections in travelers returning from the tropics. Adv Exp Med Biol. 2015; 849: 75-82.
96. Britton PN, Andresen DN. Paediatric community-associated Staphylococcus aureus: a retrospective cohort study. J Paediatr Child Health. 2013; 49 (9): 754-759.
97. Glikman D, Siegel JD, David MZ, et al. Complex molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S. aureus. Chest. 2008; 133 (6): 1381-1387.
98. Kidd TJ, Coulter C, Bell SC. Epidemiological analysis of methicillin-resistant Staphylococcus aureus isolates from adult patients with cystic fibrosis. Infect Control Hosp Epidemiol. 2006; 27 (2): 201-203.
99. Muhlebach MS, Miller M, LaVange LM, et al. Treatment intensity and characteristics of MRSA infection in CF. J Cyst Fibros. 2011; 10 (3): 201-206.
100. Besier S, Zander J, Kahl BC, et al. The thymidine-dependent small-colony-variant phenotype is associated with hypermutability and antibiotic resistance in clinical Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2008; 52 (6): 2183-2189.
101. Morelli P, De Alessandri A, Manno G, et al. Characterization of Staphylococcus aureus small colony variant strains isolated from Italian patients attending a regional cystic fibrosis care centre. New Microbiol. 2015; 38 (2): 235-243.
102. Wolter DJ, Emerson JC, McNamara S, et al. Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clin Infect Dis. 2013; 57 (3): 384-391.
103. Frei CR, Makos BR, Daniels KR, et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus skin and soft tissue infections as a common cause of hospitalization in United States children. J Pediatr Surg. 2010; 45 (10): 1967-1974.
104. Runyon EH. Anonymous mycobacteria in pulmonary disease. Med Clin North Am. 1959; 43 (1): 273-290.
105. Falkinham JO. Impact of human activities on the ecology of nontuberculous mycobacteria. Future Microbiol. 2010; 5 (6): 951-960.
106. Falkinham JO 3rd. Surrounded by mycobacteria: nontuberculous mycobacteria in the human environment. J Appl Microbiol. 2009; 107 (2): 356-367.
107. Thomson RM. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg Infect Dis. 2010; 16 (10): 1576-1583.
108. Adjemian J, Olivier KN, Seitz AE, et al. Prevalence of nontuberculous mycobacterial lung disease in U.S. medicare beneficiaries. Am J Respir Crit Care Med. 2012; 185 (8): 881-886.
109. Chou MP, Clements AC, Thomson RM. A spatial epidemiological analysis of nontuberculous mycobacterial infections in Queensland, Australia. BMC Infect Dis. 2014; 14: 279.
110. Adjemian J, Olivier KN, Seitz AE, et al. Spatial clusters of nontuberculous mycobacterial lung disease in the United States. Am J Respir Crit Care Med. 2012; 186 (6): 553-558.
111. Morimoto K, Iwai K, Uchimura K, et al. A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc. 2014; 11 (1): 1-8.
112. Thomson RM, Carter R, Tolson C, et al. Factors associated with the isolation of nontuberculous mycobacteria (NTM) from a large municipal water system in Brisbane, Australia. BMC Microbiol. 2013; 13: 89.
113. Falkinham JO 3rd. Nontuberculous mycobacteria from household plumbing of patients with nontuberculous mycobacteria disease. Emerg Infect Dis. 2011; 17 (3): 419-424.
114. Esther CR Jr., Esserman DA, Gilligan P, et al. Chronic mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros. 2010; 9 (2): 117-123.
115. Prevots DR, Adjemian J, Fernandez AG, et al. Environmental risks for nontuberculous mycobacteria. Individual exposures and climatic factors in the cystic fibrosis population. Ann Am Thorac Soc. 2014; 11 (7): 1032-1038.
116. Benedict K, Park BJ. Invasive fungal infections after natural disasters. Emerg Infect Dis. 2014; 20 (3): 349-355.
117. Frankel M, Beko G, Timm M, et al. Seasonal variations of indoor microbial exposures and their relation to temperature, relative humidity, and air exchange rate. Appl Environ Microbiol. 2012; 78 (23): 8289-8297.
118. Grinn-Gofron A, Strzelczak A. Changes in concentration of alternaria and cladosporium spores during summer storms. Int J Biometeorol. 2013; 57 (5): 759-768.
119. Oliveira M, Ribeiro H, Delgado L, et al. Outdoor allergenic fungal spores: comparison between an urban and a rural area in northern Portugal. J Investig Allergol Clin Immunol. 2010; 20 (2): 117-128.
120. Barberan A, Ladau J, Leff JW. Continental-scale distributions of dust-associated bacteria and fungi. Proc Natl Acad Sci USA. 2015; 112 (18): 5756-5761.
121. Ashbee HR, Barnes RA, Johnson EM, et al. Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British society for medical mycology. J Antimicrob Chemother. 2014; 69 (5): 1162-1176.
122. Nielsen SM, Kristensen L, Sondergaard A, et al. Increased prevalence and altered species composition of filamentous fungi in respiratory specimens from cystic fibrosis patients. APMIS. 2014; 122 (10): 1007-1012.
123. Muller FM, Seidler M. Characteristics of pathogenic fungi and antifungal therapy in cystic fibrosis. Expert Rev Anti Infect Ther. 2010; 8 (8): 957-964.
124. Shoseyov D, Brownlee KG, Conway SP, et al. Aspergillus bronchitis in cystic fibrosis. Chest. 2006; 130 (1): 222-226.
125. Jones AM, Horsley A, Denning DW. What is the importance of classifying Aspergillus disease in cystic fibrosis patients? Expert Rev Respir Med. 2014; 8 (4): 389-392.
126. Agarwal R, Khan A, Aggarwal AN, et al. Link between CFTR mutations and ABPA: a systematic review and meta-analysis. Mycoses. 2012; 55 (4): 357-365.
127. Bezerra GF, Gomes SM, Neto Silva MA, et al. Diversity and dynamics of airborne fungi in Sao Luis, State of Maranhao, Brazil. Rev Soc Bras Med Trop. 2014; 47 (1): 69-73.
128. Rangaswamy B, Francis F, Prakash K, et al. Variability in airborne bacterial and fungal population in the tertiary health care centre. Aerobiologia. 2013; 29 (4): 473-479.
129. Kanamori H, Rutala WA, Sickbert-Bennett EE, et al. Review of fungal outbreaks and infection prevention in healthcare settings during construction and renovation. Clin Infect Dis. 2015; 61 (3): 433-444.
130. Alshareef F, Robson GD. Prevalence, persistence, and phenotypic variation of Aspergillus fumigatus in the outdoor environment in Manchester, UK, over a 2-year period. Med Mycol. 2014; 52 (4): 367-375.
131. Paugam A, Baixench MT, Demazes-Dufeu N, et al. Characteristics and consequences of airway colonization by filamentous fungi in 201 adult patients with cystic fibrosis in France. Med Mycol. 2010; 48 (Suppl 1): S32-S36.
132. Morio F, Horeau-Langlard D, Gay-Andrieu F, et al. Disseminated Scedosporium/Pseudallescheria infection after double-lung transplantation in patients with cystic fibrosis. J Clin Microbiol. 2010; 48 (5): 1978-1982.
133. Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev. 2008; 21 (1): 157-197.
134. Chmiel JF, Aksamit TR, Chotirmall SH, et al. Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. Ann Am Thorac Soc. 2014; 11 (8): 1298-1306.
135. Heltshe SL, Mayer-Hamblett N, Burns JL, et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis. 2015; 60 (5): 703-712.
136. Ullrich G, Wiedau S, Schulz W, et al. Parental knowledge and behaviour to prevent environmental P. aeruginosa acquisition in their children with CF. J Cyst Fibros. 2008; 7 (3): 231-237.
137. Ullrich G, Wiedau-Gors S, Steinkamp G, et al. Parental fears of Pseudomonas infection and measures to prevent its acquisition. J Cyst Fibros. 2002; 1 (3): 122-130.
138. Ashavaid TF, Raghavan R, Dhairyawan P, et al. Cystic fibrosis in India: a systematic review. J Assoc Physicians India. 2012; 60: 39-41.
139. Naguib ML, Schrijver I, Gardner P, et al. Cystic fibrosis detection in high-risk Egyptian children and CFTR mutation analysis. J Cyst Fibros. 2007; 6 (2): 111-116.
140. Kabra SK, Kabra M, Shastri S, et al. Diagnosing and managing cystic fibrosis in the developing world. Paediatr Respir Rev. 2006; 7 (Suppl 1): S147-S150.
141. Scurati-Manzoni E, Fossali EF, Agostoni C, et al. Electrolyte abnormalities in cystic fibrosis: systematic review of the literature. Pediatr Nephrol. 2014; 29 (6): 1015-1023.
142. Demaio AR, Rockstrom J. Human and planetary health: towards a common language. Lancet. 2015; 386 (10007): e36-e37.